All news

Nurix falls 30% after hours as Sanofi drops STAT6 degrader trial and ends joint program

Investing.com · · AI-summarised by FinFlash

Nurix Therapeutics fell 30% in extended trading after partner Sanofi discontinued the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminated the joint development program, Investing.com reported. Nurix held

So What?

A setback for the oral STAT6 degrader class and for Nurix's partnership revenue. Watch how the company redeploys its cash and whether rival STAT6 programs react.

Read original source

NRIX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.